Garuda Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan 5, 2023--
Garuda Therapeutics (Garuda), a company creating off-the-shelf, durable blood stem cell therapies, today announced that Dhvanit Shah, Ph.D., Co-Founder, President and Chief Executive Officer, will present a company overview at the 41 st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 4:30 pm PT / 7:30 pm ET.
Garuda’s platform for generating off-the-shelf, self-renewing blood stem cells is designed to provide patients with rapid and broad access to consistent, durable, HLA-matched, transgene-free blood stem cell therapies. Currently, patients seeking a blood stem cell transplant must find a suitable human donor as a source of blood stem cells. Racial minority patients face significant barriers in identifying suitable blood stem cell matches. Like bone marrow transplants, Garuda’s technology has the potential to address, and possibly cure, more than 120 diseases for a diverse population of patients with unmet medical need.
About Garuda Therapeutics
Garuda Therapeutics seeks to create a world that eliminates the dependency on donor or patient cells for blood stem cell transplants. Our platform technology for generating off-the-shelf, self-renewing blood stem cells is poised to provide patients with rapid and broad access to consistent, durable, HLA-compatible and transgene-free blood stem cell therapies. Like bone marrow transplants, our technology could provide potentially curative therapies for more than 120 diseases. https://garudatx.com/
View source version on businesswire.com:https://www.businesswire.com/news/home/20230105005217/en/
Roger Sawhney, Chief Financial Officer
Megan Prock McGrath
firstname.lastname@example.org (781) 235-3060
KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS
INDUSTRY KEYWORD: BIOTECHNOLOGY HEALTH SCIENCE STEM CELLS RESEARCH
SOURCE: Garuda Therapeutics
Copyright Business Wire 2023.
PUB: 01/05/2023 09:00 AM/DISC: 01/05/2023 09:01 AM